Articles with "drug conjugates" as a keyword



Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates

Sign Up to like & get
recommendations!
Published in 2025 at "JAMA Network Open"

DOI: 10.1001/jamanetworkopen.2025.19524

Abstract: This cohort study compares population-level temporal trends in survival before and after using immune checkpoint inhibitors and antibody-drug conjugates among patients with metastatic urothelial cancer. read more here.

Keywords: antibody drug; urothelial cancer; drug conjugates; survival trends ... See more keywords
Photo from wikipedia

Polypeptides-Drug Conjugates for Anticancer Therapy.

Sign Up to like & get
recommendations!
Published in 2021 at "Advanced healthcare materials"

DOI: 10.1002/adhm.202001974

Abstract: Polypeptides are an important class of biodegradable polymers that have been widely used in drug delivery field. Owing to the controllable synthesis and robust side chain-functionalization ability, polypeptides have long been ideal candidates for conjugation… read more here.

Keywords: drug conjugates; conjugates anticancer; polypeptides drug; drug ... See more keywords

Antibody drug conjugates for the treatment of multiple myeloma

Sign Up to like & get
recommendations!
Published in 2022 at "American Journal of Hematology"

DOI: 10.1002/ajh.26750

Abstract: The treatment landscape of multiple myeloma (MM) has evolved substantially, but it remains largely incurable so new treatment options are required. Antibody drug conjugates (ADCs) are an emerging therapeutic class used in Cancer to deliver… read more here.

Keywords: drug conjugates; treatment; multiple myeloma; antibody drug ... See more keywords

Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions

Sign Up to like & get
recommendations!
Published in 2022 at "Cancer Communications"

DOI: 10.1002/cac2.12387

Abstract: Antibody‐drug conjugates (ADCs) are a rapidly developing therapeutic approach in cancer treatment that has shown remarkable activity in breast cancer. Currently, there are two ADCs approved for the treatment of human epidermal growth factor receptor… read more here.

Keywords: drug conjugates; breast cancer; resistance; antibody drug ... See more keywords

Evaluation of Potency and Specificity of Cryptophycin‐Loaded Antibody‐Drug Conjugates

Sign Up to like & get
recommendations!
Published in 2024 at "ChemBioChem"

DOI: 10.1002/cbic.202400738

Abstract: An enhanced variant of the antimitotic toxin cryptophycin was conjugated to the anti‐Her2 monoclonal antibody (mAb) Trastuzumab upon Michael addition. Either antibodies with freed hinge‐region cysteines or THIOMAB formats with engineered cysteines in the mAbs… read more here.

Keywords: cryptophycin; potency; cell; antibody drug ... See more keywords

Linker Design for the Antibody Drug Conjugates: A Comprehensive Review

Sign Up to like & get
recommendations!
Published in 2025 at "ChemMedChem"

DOI: 10.1002/cmdc.202500262

Abstract: Inspired by the “magic bullet” concept proposed over a century ago, antibody–drug conjugates (ADCs) are developed to enhance cancer therapy by linking monoclonal antibodies to a cytotoxic payload, aiming to overcome the limitations of conventional… read more here.

Keywords: linker design; drug; antibody drug; linker ... See more keywords

Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis

Sign Up to like & get
recommendations!
Published in 2022 at "Cancer"

DOI: 10.1002/cncr.34507

Abstract: Antibody–drug conjugates (ADCs) have complex molecular structures and have been tested in numerous clinical trials. Therefore, understanding the mechanisms of their toxicity when applied in medical practice is of high importance. read more here.

Keywords: clinical trials; drug conjugates; related adverse; treatment related ... See more keywords

Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?

Sign Up to like & get
recommendations!
Published in 2021 at "Clinical Pharmacology and Therapeutics"

DOI: 10.1002/cpt.2278

Abstract: Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the cytotoxicity of a chemical agent. They represent a rapidly evolving area of oncology drug development and hold significant promise. There are currently nine ADCs… read more here.

Keywords: drug conjugates; drug; food drug; antibody drug ... See more keywords

Switching positions: Assessing the dynamics of conjugational heterogeneity in antibody–drug conjugates using CE‐SDS

Sign Up to like & get
recommendations!
Published in 2022 at "Electrophoresis"

DOI: 10.1002/elps.202200140

Abstract: Antibody–drug conjugates (ADCs) are a prospective class of new oncology therapeutics with the ability to deliver a cytotoxic drug to a targeted location. The concept appears simple, but ADCs are highly complex due to their… read more here.

Keywords: drug conjugates; drug; antibody drug; conjugational heterogeneity ... See more keywords

Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes

Sign Up to like & get
recommendations!
Published in 2019 at "Journal of Cellular Physiology"

DOI: 10.1002/jcp.27419

Abstract: Targeted delivery of therapeutic molecules into cancer cells is considered as a promising strategy to tackle cancer. Antibody–drug conjugates (ADCs), in which a monoclonal antibody (mAb) is conjugated to biologically active drugs through chemical linkers,… read more here.

Keywords: drug conjugates; drug; conjugates adcs; cancer ... See more keywords
Photo from wikipedia

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates

Sign Up to like & get
recommendations!
Published in 2020 at "Journal of Clinical Pharmacology"

DOI: 10.1002/jcph.1720

Abstract: Antibody‐drug conjugates are important molecular entities in the treatment of cancer, with 8 antibody‐drug conjugates approved by the US Food and Drug Administration since 2000 and many more in early‐ and late‐stage clinical development. These… read more here.

Keywords: drug conjugates; drug; pharmacology; antibody drug ... See more keywords